This site is intended only for US Healthcare Professionals
With multiple gene therapy clinical trials for hemophilia B in later stages of review, it’s time to start thinking about gene therapy and your practice.
Whether your institution is ready to administer, or willing to refer, preparing the comprehensive care team within your practice for gene therapy is important for your patients.
Considerations might include site readiness and required staff training to support the business and administrative needs of a new treatment option.
Connect with CSL Behring to learn more about site readiness
Each gene therapy under investigation has unique limitations that need to be understood. Potential eligibility requirements to consider with your hemophilia B patients may include comorbidities, factor inhibitors, and the presence of potential neutralizing antibodies (NAbs) to AAV.
Employing a shared decision-making approach will help people with hemophilia B make the right treatment decisions. It will be important to set expectations with your patients about their eligibility for and risks of gene therapy. You should also inform patients gene therapy will require a period of monitoring their health and making lifestyle adjustments.
Watch Dr. George discuss how healthcare professionals can prepare to answer patient questions about gene therapy.
Sign up for news of advances in gene therapy for hemophilia B.
SIGN UP NOW >